Latest Conference Articles

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.

An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

Luis E. Raez, MD, discusses how oral TKIs may shift frontline sequencing across ROS1-positive, HER2-mutant, and EGFR exon 20 insertion–positive NSCLC.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Rajwanth R. Veluswamy, MD, MSCR, discusses universal KRAS testing, the frontline immunotherapy signal in KRAS G12C+ NSCLC, and next-generation G12C inhibitors.

Luis E. Raez, MD, discusses molecular testing, screening gaps, and global drug access challenges in lung cancer across Latin America and the US.

Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses phase 1 dose-optimization data supporting the 2.5 mg/kg dose of iza-bren in EGFR-mutated NSCLC.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.

Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.

Stephen V. Liu, MD, discusses building on durvalumab consolidation with tarlatamab and other novel agents in limited-stage SCLC.

Enriqueta Felip, MD, PhD, discusses selecting next-generation ROS1 TKIs after progression on crizotinib or entrectinib in NSCLC.

Luis Paz-Ares, MD, PhD, discusses protocols for managing T-cell engager and antibody-drug conjugate toxicities in lung cancer.

Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.

Tetsuya Mitsudomi, MD, PhD, discusses classifying and individualizing treatment for uncommon EGFR mutations in NSCLC.

Yang Xia, MD, PhD, discusses strategies for overcoming EGFR TKI resistance, including biomarker-selected and -unselected approaches.

Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.

Molly Li, MBBS, discusses selecting between HER2-directed TKIs and antibody-drug conjugates in first-line HER2-mutant NSCLC.

First data from the phase 1B/2 BNT324-01 trial pair a PD-L1 and VEGF-A bispecific antibody with a B7H3-directed ADC in patients with SCLC.

Every-3-week and every-4-week tarlatamab regimens produced ORRs of 31% and 27% vs 40% with standard bi-weekly dosing in the phase 2 DeLLphi-309 trial.

The dose-finding DeLLphi-308 trial showed promising results for a more convenient administration of tarlatamab in patients with ES-SCLC.

The phase 3 LONESTAR trial was closed early for futility after added local consolidative therapy showed no OS or PFS benefit, including in oligometastatic disease.

Grant outlines open questions in perioperative NSCLC, from neoadjuvant sequencing and adjuvant selection to whether ctDNA is ready for practice.

A hematology-oncology fellow explains how trainees can use poster walks, follow-up contact, and review articles to find mentors and generate research questions.

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.

Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.